Argenx Se · EURONEXT:ARGX
Argenx — Q1 2023 Earnings Presentation
13 slides from Argenx's earnings presentation, May 4, 2023
Slide 1: First Quarter 2023 Financial Results and Business Update
First Quarter 2023 Financial Results and Business Update May 4, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Continued Progress Across Business
Continued Progress Across Business 5 Global VYVGART $218M Approvals Reaching in global product revenues Geographic US, Japan, EU, UK and Israel More gMG in first quarter 2023 Expansion Patients Planned SC Approval Broaden Pioneer FcRn ARGX-117 and ARGX-119 Class of June 20th PDUFA Date Immunology Ad
Slide 4: Redefining What 'Well-Controlled' Means for the Patient
Redefining What ‘Well-Controlled’ Means for the Patient We want to transform gMG treatment for patients Achieve minimal symptom expression Reduce reliance on broad immunosuppressants Minimize treatment burden Regain control of their lives, including professionally and socially 4
Slide 5: Steady Cadence of Upcoming Data Readouts
Steady Cadence of Upcoming Data Readouts clinical 2024 DATA July 2023 Fourth Quarter 2023 2024 READOUTS Myositis* ITP Efgartigimod 57K 63K CIDP PC-POTS 16K >500K Pemphigus BP* 19K 52K 2023 DATA Mid-2023 ARGX-117 READOUTS MMN 6K *GO/NO GO Decisions. 5 Patient numbers are U.S. prevalence from argenx m
Slide 6: ARGX-117: First Clinical Efficacy Data Expected Mid-2023
ARGX-117: First Clinical Efficacy Data Expected Mid-2023 clinical Broaden immunology ARGX-117: 2024 DATA MMN: Interim Phase 2 Data Expected Mid-2023 pipeline READOUTS Sweeping Antibody Confirm safety profile in MMN patients pH and Ca2+ switch Measure extent of complement blockade with initial dose s
Slide 7: ARGX-119: MuSK Agonist with Broad Potential in Neuromuscular Disease
ARGX-119: MuSK Agonist with Broad Potential in clinical Neuromuscular Disease Broaden immunology pipeline First-in-Human Phase 1 Healthy Volunteer Study First-in- Patient Single Ascending Dose Multiple Ascending Dose Congenital Myasthenic 10 dose cohorts Syndrome (CMS) 3 dose cohorts/4 weekly doses
Slide 8: First Quarter 2023 Revenue Update
First Quarter 2023 Revenue Update 2023 DATA $218M Total Q1 2023 Product Net Sales Breakdown by Region READOUTS QoQ % (in millions of $) Q1 2023 Q4 2022 Growth* US 196 159 23% Japan 10 8 16% 218 Europe 10 5 82% 173 131 Other** 2 1 168% 75 Total 218 173 25% 21 Q1 Q2 Q3 Q4 Q1 2022 2022 2022 2022 2023 *
Slide 9: First Quarter 2023 Financial Results
First Quarter 2023 Financial Results Three ThreeMonths monthsEnded ended March 31 (in millions of $) 2023 2022 Product net sales 218 21 Collaboration revenue and other 12 10 Total operating income 230 31 Cost of sales (18) (1) R&D expenses (166) (152) SG&A expenses (149) (101) Total operating expens
Slide 10: We are on a bold mission
We are on a Co-Creation Empowerment bold mission Transforming the lives of patients with Innovation Excellence severe autoimmune disease through immunology innovation Humility 10
Slide 11: Optimizing Core Launch Strategies
Optimizing Core Launch Strategies VYVGART launched in US, Patients Driving physicians to prescribe in Japan and Germany earlier line therapies Payors SUBMISSIONS IN 50% of patients 10+ COUNTRIES have IVIg experience Physicians Early engagement with payors Broadest offering to gMG to enable access fo
Slide 12: Global gMG Launch Progressing
Global gMG Launch Progressing VYVGART Approved SC Efgartigimod PDUFA December 2021 June 20, 2023 United States Japan United Kingdom China (Zai Lab) Approved January 2022 Approved March 2023 Expected approval in 2023 Europe Israel (Medison) Canada Approved September 2022 Approved April 2023 Expected
Slide 13: ...and gMG is just the beginning
Lead with Pioneer with Compassion for Our Science our Patients …and gMG is just the argenx 2025: A Leading, Sustainable Immunology Company beginning Build the Drive Impact Company We Through Want to Work Innovation For 13